Overview

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).

Phase:

Phase 1

Details

Lead Sponsor:

Myovant Sciences GmbH

Treatments:

Docetaxel
Methylprednisolone
Prednisone
Relugolix